Latest Development Activity News

Lion Rock Minerals announces a leadership transition as CEO Casper Adson steps into a technical advisory role, with the Board seeking a new CEO to strengthen on-ground presence and accelerate exploration at the Minta Project in Cameroon.

Nexalis Therapeutics reported a widening loss of $1.83 million for 2025, reflecting increased investment in product development and marketing. Despite the loss, the company boosted its cash reserves through equity raises and borrowings.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

Terra Metals has raised $85 million through an institutional placement to fast-track exploration and development of its promising Southwest Prospect within the Dante Project in Western Australia.

Bass Oil reported steady January production with a notable regulatory green light for its Vanessa gas field acquisition and a $3.5 million grant to accelerate the Kiwi gas field development.

Freehill Mining Limited has secured options to acquire a portfolio of promising copper-gold projects in Chile, including a JORC-compliant resource at Blanco y Negro and extensive exploration potential at Joshua and Samuel. The deal features low upfront payments and milestone-based future costs, aligning with Freehill’s growth strategy supported by its cash-generating aggregates business.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.

GoldArc Resources has locked in a strategic drilling services agreement with MMS for its Leonora South Gold Project, enabling up to A$750,000 of drilling fees to be paid in shares. This innovative deal preserves cash and aligns contractor incentives with the project’s long-term success.

Patrys Limited reported a near doubling of its half-year loss to $3.02 million, driven by restructuring and a strategic pivot including the acquisition of Reliis Pty Ltd. The company is advancing a dual-platform biotech strategy combining a clinical-stage CNS asset with its proprietary antibody platform.

Auravelle Metals has appointed seasoned geologist Stephen Biggins as Non-Executive Chair, marking a strategic leadership shift as the company advances its high-grade gold projects in South Australia and Western Australia.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.